Cisplatin–epirubicin–paclitaxel weekly administration with G-CSF support in advanced breast cancer. A Southern Italy Cooperative Oncology group (SICOG) phase II study Giuseppe FrasciGiuseppe D'AiutoGiuseppe Comella OriginalPaper Pages: 87 - 97
Transcriptional suppression of synuclein γ (SNCG) expression in human breast cancer cells by the growth inhibitory cytokine oncostatin M Jingwen LiuMichael J. SpenceY. Eric Shi OriginalPaper Pages: 99 - 107
Inducible expression of herpes simplex virus thymidine kinase increases sensitivity to ganciclovir but does not enhance bystander effect in breast cancer cells Ravi PatilJeffery B. ChavezDouglas Yee OriginalPaper Pages: 109 - 115
Flow cytometry in primary breast carcinomas. Prognostic impact of proliferative activity Jean-Jacques MichelsFrançoise DuigouJacques Marnay OriginalPaper Pages: 117 - 126
A phase II trial of cyclophosphamide, epirubicin and vinorelbine in the treatment of advanced breast cancer E. EstebanGonzález de SandeA.J. Lacave OriginalPaper Pages: 127 - 133
Five-day infusion fluorouracil plus vinorelbine in women with breast cancer previously treated with anthracyclines and paclitaxel M. ZambettiG. MarianiF. Garbagnati OriginalPaper Pages: 135 - 139
Quality of life after adjuvant chemotherapy for breast cancer Jo Ann BroeckelPaul B. JacobsenGary H. Lyman OriginalPaper Pages: 141 - 150
Characterization of a novel silencer element in the human aromatase gene PII promoter Tianru JinXiaoyun ZhangPaul E. Goss OriginalPaper Pages: 151 - 159
